

ABSTRACT

A method for monitoring the effectiveness of an administered agent that interacts with the A₃ adenosine receptor (A₃AR) in treatment of a disease state in an individual is provided. The level of at least one parameter of a biological marker is determined and compared to a control level, the control level being the level of the parameter without treatment, which is determined either as the level of the parameter in the individual prior to treatment or the level of the parameter in untreated control subject having the disease state. Monitoring a change in these parameters versus control, may also be used for screening agents that interact with the A₃AR for such that can be used for a treating a disease state.